Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

Phase 1

2(33.3%)

Phase 3

1(16.7%)

N/A

1(16.7%)

6Total

Phase 2(2)

Phase 1(2)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01321216Completed

Rotavirus Burden and Genotypes in a Sentinel Hospital Surveillance System in Lebanon

Role: collaborator

NCT03748732Not ApplicableUnknown

Extensive Circumferential Partial Thickness Sclerectomy in Nanophthalmic Eyes

Role: lead

NCT02486484Phase 2Unknown

Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection

Role: lead

NCT02819622Completed

Persona of Central Serous Chorioretinopathy

Role: lead

NCT02804360Phase 2Unknown

Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study

Role: lead

NCT01315366Phase 3Completed

Hypovitaminosis D : A Link Between Bone/Mineral and Fat/Fuel Metabolism

Role: collaborator

NCT02173873Phase 1Unknown

Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I

Role: lead

NCT00855608Phase 1Unknown

Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study

Role: lead

NCT00645697Completed

Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization

Role: lead

All 9 trials loaded